Laboratory Action Plan for Emerging SARS-CoV-2 Variants.
Laboratory Action Plan for Emerging SARS-CoV-2 Variants.
复制标题
新兴 SARS-CoV-2 变种实验室行动计划。
DOI：
10.1093/clinchem/hvab020
复制
发表时间：
2021
影响因子：
9.3
通讯作者：
Park,JasonY
中科院分区：
文献类型：
--
作者：
Filkins,Laura;SoRelle,JeffreyA;Schoggins,John;Park,JasonY
背景2020年12月，在英国发现了一种具有临床意义的SARS-CoV-2变异株，其传播率增加（1-3）。目前称为SARS-CoV-2 VOC-202012/01（关注变体，2020年，12月，变体; VOC-202012/01）或B。1.1. 7变种，它已在世界各地的多个国家被确定，并继续蔓延有增无减（1，4）。VOC-202012/01似乎可以通过美国食品药品监督管理局（FDA）紧急使用许可（EUA）的常用核酸检测检测来检测，希望不会对临床实验室造成诊断挑战。随着COVID-19大流行的持续，我们预计将出现更多具有临床意义的SARS-CoV-2变种，我们建议临床实验室采取几项准备行动。
BackgroundIn December 2020, a clinically significant SARS-CoV-2 variant with an increased transmission rate was identified in the United Kingdom (1–3). Currently referred to as SARS-CoV-2 VOC-202012/01 (Variant of Concern, year 2020, month 12, variant; VOC-202012/01) or the B. 1.1. 7 variant, it has been identified in multiple countries throughout the world and continues to spread unabatedly (1, 4). VOC-202012/01 appears to be detectable by commonly used nucleic acid-based tests with emergency use authorization (EUA) from the United States Food and Drug Administration (FDA), and hopefully will not present a diagnostic challenge for clinical laboratories. As the COVID-19 pandemic continues, we anticipate additional clinically significant SARS-CoV-2 variants will emerge and we propose several preparatory actions for clinical laboratories.